Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...
IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...
While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...
Hosted on MSN18d
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?Summit's market cap shot above $23 billion in September after investors saw interim results of the Harmoni-2 trial. The study ...
Keytruda racked up a stunning $25 billion in ... Despite having no products to sell, Summit's market cap shot above $23 billion in September after investors saw interim results of the Harmoni ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback